Ubiquinol vs Ubiquinone: CoQ10 Forms Compared

Ubiquinone is the oxidized form of CoQ10, while ubiquinol is the reduced form. Both participate in the same biological redox cycle. Reduced does not mean undiluted, more potent by definition, or the only form the body can use. Oxidized does not mean damaged or inactive. ^{3, 5}

The practical label difference is the form placed in the capsule or softgel. The supplement still needs a disclosed active amount, a defined serving, a credible formulation, and evidence relevant to that product’s claim.

Ubiquinone and ubiquinol are interconverted in the body. In a randomized crossover study of 21 healthy adults aged 65 to 74, circulating CoQ10 appeared mostly as ubiquinol after participants consumed ubiquinone, ubiquinol, or a water-soluble ubiquinone formulation. ³

This does not make the starting form irrelevant. It does show why the claim that only pre-reduced CoQ10 is usable is too simple. The product’s dissolution, carrier, dose, meal context, and the user can affect how much CoQ10 reaches circulation.

CoQ10 is fat-soluble and poorly water-soluble. Crystal dispersion, carrier lipids, solubilization, particle behavior, and dosage form can therefore change absorption. A review of commercial products concluded that carrier lipids and solubilization were important drivers of bioavailability. ^{2, 5}

In the 2020 three-product crossover study, a water-soluble ubiquinone formulation produced 2.4 times the exposure of the standard ubiquinone product. The tested ubiquinol capsule produced a 1.7-fold estimate, but its difference from standard ubiquinone was not statistically significant. This is a product-specific comparison, not a ranking of every water-soluble or ubiquinol product. ³

Another small crossover trial compared 200 mg per day of ubiquinol and ubiquinone for two weeks in 10 older men. Ubiquinol produced a larger increase in plasma CoQ10 in that study, although responses differed between participants and neither form changed peripheral blood mononuclear cell (PBMC) CoQ10 or oxidative-stress biomarkers. This supports a possible formulation-specific exposure difference without establishing a superior health outcome. ⁶

A small 2026 crossover study in 12 healthy adults found higher exposure from a novel cocrystal ubiquinol softgel than from its ubiquinone reference under fasting conditions. The finding belongs to those two tested formulations, the small study population, and that dosing condition. It does not create a universal absorption multiplier for all ubiquinol labels. The study was funded by the company that supplied the test and reference products, which is relevant context when interpreting the result. ⁴

Keep the active CoQ10 milligrams separate from carrier-oil, phospholipid, cyclodextrin, or proprietary delivery-complex mass. If a label lists a 300 mg delivery complex that contains 100 mg of CoQ10, the active CoQ10 comparison remains 100 mg.

Ubiquinol commonly costs more, but a higher price does not measure absorption or outcome. First normalize both products to the full listed serving and the disclosed active CoQ10 milligrams. Then note the delivery system and whether its comparative evidence matches the exact finished product.

Pharmacokinetic studies measure values such as peak concentration and area under the concentration curve. These can show that one tested formulation produced more systemic exposure. They do not by themselves show that the product improves fatigue, heart function, migraine, statin-related symptoms, exercise, or healthy aging.

Clinical claims must be evaluated separately using trials that match the population, outcome, dose, duration, background care, and actual formulation. The broader CoQ10 supplement guide covers those claim-specific evidence limits. This page answers the narrower form and formulation question.